Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:02:24.939Z.
Calculation as of: 2026-10-06T16:02:24.939Z.
Quote observation: 2026-10-06T15:59:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $477.27M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $479.06M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $472.58M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $474.22M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $472.48M | N/A | 0.08 | 0.16 | 0.16 |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.85M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $491.28M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $462.12M | N/A | 6.07 | 3.14 | 2.42 |
| Oculis Holding AG (OCS)vs › | $498.55M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $451.59M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute